Study: Tarceva delays lung cancer twice as long

In a boost for its cancer drug Tarceva, Roche reported new data showing the drug kept one form of advanced lung cancer at bay for almost twice as long as standard treatment. Genentech release | Report

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.